Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun:3:155-159.
doi: 10.1016/j.pvr.2017.04.005. Epub 2017 Apr 28.

Detection of cervical precancerous lesions with Aptima HPV assays using SurePath preservative fluid specimens

Max Chernesky  1 , Dan Jang  2 , Nick Escott  3 , Jodi Gilchrist  2 , Jenny Li  2 , Laurie Elit  4 , Alice Lytwyn  4 , Marek Smieja  2 , Sam Ratnam  5 , Manuel Arias  2 , Damon Getman  6 , Barbara Weinbaum  6 , Brett Kirkconnell  6 , Janel Dockter  6
Affiliations

Detection of cervical precancerous lesions with Aptima HPV assays using SurePath preservative fluid specimens

Max Chernesky et al. Papillomavirus Res. 2017 Jun.

Abstract

SurePath specimens from women referred to colposcopy were treated with Aptima Transfer Solution (ATS) before testing in Aptima HPV (AHPV) and Aptima HPV 16, 18/45 (AHPV-GT) assays. Untreated SurePath specimens were tested with the cobas HPV test. PreservCyt specimens were assessed for cytology and tested with AHPV. High-grade cervical intraepithelial neoplasia lesions served as the reference standard. Excellent agreement (95.5%; k=0.91) was observed for ATS-treated SurePath specimens between Tigris and Panther systems and between the PreservCyt and ATS-treated SurePath specimens (91.1%, k=0.81) with the AHPV assay on Tigris. Agreement between the AHPV and cobas assays with SurePath specimens was substantial (89.9%, k=0.80). AHPV sensitivity for CIN2+(n=147) was 91.2% for SurePath and PreservCyt. Cobas HPV sensitivity was 93.9% for SurePath specimens. AHPV testing of SurePath specimens was more specific (59.4%) than cobas (54.7%) (p<0.001). Detection and genotyping showed similar absolute and relative risks. ATS-treated SurePath specimens tested with AHPV and AHPV-GT assays showed similar performance with greater specificity than cobas HPV on SurePath specimens. Similar overall results were seen using a CIN3 disease endpoint.

Keywords: Aptima transfer solution (ATS); CIN2+,; Cervical intraepithelial neoplasia; Human papillomavirus; PreservCyt; SurePath.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1
Study scheme.
See this image and copyright information in PMC

References

    1. Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J. Clin. 2012;62(3):147–172. - PMC - PubMed
    1. Szarewski A., Mesher D., Cadman L., Austin J., Ashdown-Barr L., Ho L. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 Study. J. Clin. Microbiol. 2012;50(6):1867–1873. - PMC - PubMed
    1. Clark-Gero M., Pitlik D., Barcelo M. Human papillomavirus testing using Roche Cobas HPV test with surepath preparation in gynecologic cytology. Am. J. Clin. Pathol. 2015;144(2):A237.
    1. Gilbert L., Oates E., Ratnam S. Stability of cervical specimens in SurePath medium for human papillomavirus testing with the Roche cobas 4800 assay. J. Clin. Microbiol. 2013;51(10):3412–3414. - PMC - PubMed
    1. Davis-Devine S., Day S.J., Freund G.G. Test performance comparison of inform HPV and hybrid capture 2 high-risk HPV DNA tests using the SurePath liquid-based Pap test as the collection method. Am. J. Clin. Pathol. 2005;124(1):24–30. - PubMed

LinkOut - more resources